STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3252 by analyst upside · 2026-08-13
PTGX
Protagonist Therapeutics, Inc.
Healthcare · Market Cap $10B · P/E 149.0x
ANALYST PRICE TARGET
+8.7%
implied upside to consensus target
Current Price $152.01
Consensus Target $165.31
Bull Target $225.0
Bear Target $112.0
Analysts Covering 13
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
10
Hold
0
Sell
0
52-Week Low $54.18
52-Week High $152.7
YTD Return +74.4%
FUNDAMENTALS
Market Cap $10B
P/E Ratio (TTM) 149.0x
Forward P/E N/A
EPS (TTM) $1.02
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $282M
Profit Margin 29.4%
52-WEEK RANGE
52-Week Low $54.18
52-Week High $152.7
Current Price $152.01
Bear Target $112.0
Bull Target $225.0
● Now $152.01 ● Target $165.31
TRADING DATA
Avg Volume 685K
YTD Return +74.4%
Analyst Count 13
Consensus Buy
Upside to Target +8.7%
Last Updated 2026-08-13

ANALYST SUMMARY

Protagonist Therapeutics, Inc. (PTGX) is currently trading at $152.01 with a Wall Street consensus price target of $165.31, implying potential upside of 8.7% over the next 12 months. 13 analysts currently cover PTGX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $225.0, while the most cautious has a target of $112.0.

PTGX operates in the Healthcare sector with a market capitalisation of $10B. The stock is up 74.4% year-to-date and is currently trading near the upper end of its 52-week range of $54.18 – $152.7.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PTGX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citizens - Reiterated
Market Outperform → Market Outperform 2026-05-06 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-05-06 Building track record
Truist Securities - Reiterated
Buy → Buy 2026-04-15 Building track record
Clear Street - Reiterated
Buy → Buy 2026-04-07 Building track record
Leerink Partners - Reiterated
Outperform → Outperform 2026-03-19 29% win rate (7 calls)
JP Morgan - Reiterated
Overweight → Overweight 2026-03-19 43% win rate (7 calls)
Citigroup - Reiterated
Buy → Buy 2026-03-19 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-03-19 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
62
out of 100
Coverage depth
20/30
Consensus clarity
15/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →